🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Pancreatic Carcinoma

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413Phase 12 sites📍 Fairway📍 Bethesda National Cancer Institute (NCI) · Tests: Metarrestin A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites📍 Birmingham📍 Birmingham📍 Birmingham Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046054, pembrolizumab CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma NCT06861452Phase 1, Phase 21 site📍 Modena EIR Biotherapies s.r.l. · Tests: RR001 Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer NCT07408505NA1 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Nano-crystalline megestrol acetate, First-line Chemotherapy TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors NCT07360314Phase 19 sites📍 New Haven📍 Huntersville📍 Galveston EMD Serono Research & Development Institute, Inc. · Tests: M7437, M7437 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors NCT05932862Phase 116 sites📍 Fountain Valley📍 Jacksonville📍 Orlando Exelixis · Tests: XL309, Olaparib AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113Phase 139 sites📍 Duarte📍 Los Angeles📍 Atlanta Amgen · Tests: AMG 410, Pembrolizumab, Panitumumab Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC) NCT07407231NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Ablative Stereotactic Body Radiotherapy (SBRT), Standard First-Line Chemotherapy Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer NCT06984562NA1 site📍 Philadelphia Fox Chase Cancer Center · Tests: Adaptive Radiation Therapy Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy NCT07892573NA1 site📍 Ningbo Ningbo Medical Center Lihuili Hospital · Tests: Becotatug Vedotin, Anti-PD-1 antibody, S-1 A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581Phase 146 sites📍 Orange📍 Santa Monica📍 Chicago Astellas Pharma Global Development, Inc. · Tests: ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer NCT04276857NA2 sites📍 Regina📍 Saskatoon University of Saskatchewan · Tests: Irreversible electroporation (NanoKnife® ) A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150Phase 19 sites📍 Boston📍 San Antonio📍 San Antonio PAQ Therapeutics, Inc. · Tests: PT0511, Cetuximab A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035Phase 19 sites📍 Denver📍 Chicago📍 Grand Rapids Context Therapeutics Inc. · Tests: CT-95 Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor NCT03093688Phase 1, Phase 21 site📍 Shanghai Shanghai Public Health Clinical Center · Tests: Infusion of iNKT cells and CD8+T cells Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369NA1 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: individualized mRNA neoantigen vaccine (mRNA-0523-L001) Surgery for Locally Unresectable Pancreatic Cancer NCT07241663n/a1 site📍 Padova Azienda Ospedaliera di Padova · Tests: Questionnaire TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors NCT05740956Phase 11 site📍 Beijing Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: HS-10502 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer NCT06761027Phase 1, Phase 24 sites📍 Fuzhou📍 Fuzhou📍 Fuzhou Fujian Provincial Hospital · Tests: Anlotinib combined with Sintilimab Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Phanes Therapeutics · Tests: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy